Asthma and CRSwNP: Raising the Bar with Remission

Remission has emerged as the new benchmark in the treatment of both asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), representing a shift from the traditional goal of symptom control to a more ambitious and comprehensive standard of care. For years, the concept of remission was overlooked in these conditions, unlike in many other chronic diseases. That paradigm is now changing. Advances in treatment—including targeted therapies, personalised approaches, preventive strategies, and multidisciplinary care—are enabling clinicians to pursue remission as a realistic goal for patients with severe asthma and CRSwNP.

To support this evolution, EUFOREA has released a consensus statement defining remission in both asthma and CRSwNP. This initiative aims to align the language used by healthcare professionals while also helping patients better understand the objectives of their treatment. Remission is no longer just an aspirational goal—it is fast becoming the “holy grail” of modern respiratory care.

In this episode, EUFOREA invites Professor Yvonne Chan, an Otolaryngologist-in-Chief based at St. Michael's Hospital in Toronto, and Associate Professor in the Department of Otolaryngology - Head & Neck Surgery at the University of Toronto, and Professor Michael Wechsler, Professor of Medicine at the National Jewish Health hospital based in Denver, Colorado in the United States, and Director, NJH Cohen Family Asthma Institute in the Division of Pulmonary, Critical Care and Sleep Medicine.